Leveraging off China Grand Pharma’s capabilities and infrastructure in
The material terms of the partnership include:
Therapeutic Products
US$25M (~AU$35M) up-front non-refundable prepayment toTelix , to be credited against future regulatory and commercial milestone payments.- Up to
US$225M (~AU$315M) in regulatory and commercial milestone payments toTelix , across Telix’s existing therapeutic products portfolio. - Program-related investment estimated at up to
US$65M (~AU$90M) for clinical costs associated with the development of the therapeutic products in the Territory, to align with Telix’s global clinical development programs. - Royalties on therapeutic product sales in the Territory, in addition to milestone payments.
Imaging Products
- Exclusive commercial partnership (sales, marketing, distribution) for Telix’s core imaging product portfolio:
- TLX250-CDx (89Zr-Girentuximab) for renal cancer, and;
- TLX591-CDx (68Ga-PSMA), TLX599-CDx (99Tc-PSMA) for prostate cancer.
- TLX250-CDx (89Zr-Girentuximab) for renal cancer, and;
- Includes minimum annual purchase obligations to maintain Territory exclusivity.
Strategic
Additionally, China Grand Pharma will make a simultaneous one-time strategic equity investment of
China Grand Pharmaceutical and Healthcare Holdings Executive Deputy Officer, Mr.
About the China Opportunity
In
- Prostate cancer: The prevalence of prostate cancer in
China is heavily weighted to urban versus rural areas (14/100,000 versus 5/100,000, respectively) and men are first diagnosed with more advanced stage disease compared to their Western counterparts (localised; locally advanced; metastatic: 40%; 30%; 30% versus 84%; 12%; 4% in Chinese versus Western men, respectively).5 Consequently, there is a significant unmet need for effective prostate cancer imaging for the improved diagnosis and staging of prostate cancer inChina , as well as more effective systemic therapies to address the high rate of advanced forms of the disease. - Renal cancer: Renal cancer is the third most common urologic cancer, after prostate and bladder cancers in
China , and most patients are diagnosed as incidental findings from abdominal imaging.6 Similar to Western countries, there are major unmet needs inChina for improvement in diagnosis of renal cell carcinoma (typically the most common and aggressive form of kidney cancer) from otherwise indeterminate renal masses using PET imaging, as well as effective treatments for advanced (metastatic) forms of this disease. - Glioblastoma: The diagnosis of glioblastoma, the most common type of primary brain cancer is typically considered incurable in
China . While surgical resection plus radiation therapy are the mainstays of treatment, the vast majority of patients experience disease recurrence. Thus, there remains a major need for therapies targeted towards glioblastoma in patients in both the front-line treatment setting, as well as for patients experiencing disease recurrence following surgical intervention.7
About
About China Grand Pharmaceutical and Healthcare Holdings
China Grand Pharmaceutical and Healthcare Holdings Limited (512.HK) is a diversified global pharmaceutical enterprise, principally engaged in research, development, manufacturing and sales of pharmaceutical products, advanced medical devices, specialized pharmaceutical ingredients, biotechnology products and nutritional products. CGP’s core product portfolio covers several major therapeutic areas including respiratory and ENT, cardiovascular emergency products and advanced medical devices, bio-technology products and nutritional products. The business is structured into four major segments: innovative medicines and medical devices with high barriers of entry; branded drugs; pharmaceutical ingredients and products; and nutritional products. For more information visit www.chinagrandpharm.com.
Telix Corporate Contact | CGP Corporate Contact |
Dr. | Mr. |
CBO and Head of Investor Relations | Executive Deputy Officer |
Email: david.cade@telixpharma.com | Email: zhouc@chinagrandinc.com |
_________________________________
1 Territory includes mainland
2 Source: http://chinagrandpharm.com/history/
3 Source: http://www.sirtex.com/au/media/news/news-item?id=38760
4 Globocan 2018 http://gco.iarc.fr/today/data/factsheets/populations
5 Chinese guidelines for diagnosis and treatment of prostate cancer 2018 (English version)
6 Globocan 2018 http://gco.iarc.fr/today/data/factsheets/populations
7 Chang L, et al. Treating malignant glioma in Chinese patients: update on temozolomide. OncoTargets and Therapy 2014:7 235–244.
© OMX, source